Bupropion
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Bupropion
- Bupropion: From Depression and Smoking Cessation to Attention Deficit Hyperactivity Disorder
Bupropion: From Depression and Smoking Cessation to Attention Deficit Hyperactivity Disorder
One-Sentence Summary
Bupropion was originally used to treat depression and to help people stop smoking (nicotine dependence). The TxGNN model predicts it may be effective for attention deficit hyperactivity disorder (ADHD), with 6 clinical trials (including one completed Phase 3 randomized, placebo-controlled trial) and 20 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Major depressive disorder and nicotine dependence (the only New Zealand licence on record has no indication text) |
| Predicted New Indication | Attention deficit hyperactivity disorder |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L2 (see note below) |
| New Zealand Market Status | Cancelled only (no currently valid licence) |
| Number of Authorizations | 1 (cancelled) |
| Recommended Decision | Proceed with Guardrails |
Note on evidence level: the data compiled for this report labels the evidence as L1, but only one completed Phase 3 trial is listed (NCT00048360). Under the stated rules, L1 requires at least two completed Phase 3 RCTs, so L2 is the more conservative grade. The Phase 2/3 trial NCT00061087 does not have a confirmed bupropion arm.
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on general pharmacological knowledge, bupropion inhibits the reuptake of norepinephrine and dopamine (the pharmacology data lists the norepinephrine transporter NET and the dopamine transporter DAT as targets). It has no serotonergic activity.
Established ADHD treatments such as methylphenidate and atomoxetine also act on the dopamine and norepinephrine systems. This overlap gives bupropion biological plausibility in ADHD. Its efficacy in depression and nicotine dependence is already established, and ADHD frequently co-occurs with both conditions.
Several reviews list bupropion as a second-line or non-stimulant option for adult ADHD, mainly for patients who do not respond to or cannot tolerate stimulants.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00048360 | Phase 3 | Completed | 162 | 8-week randomized, double-blind, placebo-controlled, flexible-dose trial of extended-release bupropion (300-450 mg/day) in adults with ADHD; strongest direct evidence |
| NCT00061087 | Phase 2/3 | Completed | 115 | Treatment of adult ADHD in methadone-maintained patients; the study drug and control design are not stated in the available data |
| NCT00936299 | Phase 4 | Completed | 105 | Bupropion for ADHD in adolescents with substance use disorder |
| NCT01270555 | NA | Completed | 32 | Open study of bupropion SR in adults with ADHD and recent or current substance use disorders |
| NCT00000268 | NA | Completed | 32 | Cocaine abuse with ADHD; small sample, mainly substance-use focus |
| NCT04553263 | Early Phase 1 | Withdrawn | 0 | Relapse prevention in stimulant use disorder; withdrawn with no participants, so no usable evidence |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 28965364 | 2017 | Cochrane systematic review | Cochrane Database Syst Rev | Dedicated review of bupropion for ADHD in adults, as an alternative when psychostimulants are not tolerated or not effective |
| 30097390 | 2018 | Network meta-analysis | Lancet Psychiatry | Comparative efficacy and tolerability of ADHD medications across children, adolescents and adults |
| 33085721 | 2020 | Network meta-analysis | PLoS One | Relative effects of pharmacologic treatments for adult ADHD |
| 40203844 | 2025 | Network meta-analysis (cardiovascular safety) | Lancet Psychiatry | Compares effects of ADHD medications on haemodynamic and ECG parameters |
| 37405312 | 2023 | Review | Health Psychol Res | Bupropion pharmacology and its use in depression, ADHD and smoking cessation |
| 38915262 | 2024 | Review | Expert Rev Neurother | Nonstimulant medications for adults with ADHD |
| 39172673 | 2024 | Review | Am Fam Physician | Overview of ADHD diagnosis and treatment in adults |
| 26601963 | 2016 | Review | Curr Pharm Des | Effects and side effects of ADHD drugs, including bupropion as a commonly used option |
| 27738872 | 2017 | Network meta-analysis | Mol Neurobiol | Efficacy and safety of ADHD treatments in children and adolescents |
| 19023824 | 2008 | Post hoc analysis | Nicotine Tob Res | Smoking cessation outcomes by ADHD symptom type in 583 adult smokers treated with bupropion and nicotine patch |
New Zealand Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 2439743 | Zyban (cancelled) | Modified-release tablet 150 mg | Not recorded |
Bupropion currently has no valid single-ingredient or combination licence in New Zealand. Any ADHD use would therefore require a new market authorisation or an unapproved-medicine pathway.
Safety Considerations
- Contraindications suggested by the knowledge graph (these are drug-disease links from the TxGNN knowledge graph, not package insert text): epilepsy, anorexia nervosa, bulimia nervosa, bipolar mania, psychotic disorders, substance abuse/dependence, opiate dependence, hypertension, liver disease or failure, cirrhosis, kidney disease, myocardial infarction, and central nervous system neoplasm.
- Relevance to the ADHD population: many candidate patients have comorbid substance use disorder, anxiety or psychiatric conditions, which overlap with several of these flagged conditions. Seizure risk and cardiovascular effects deserve particular attention.
- Pharmacological targets: bupropion acts on NET and DAT, consistent with its dopamine and norepinephrine reuptake inhibition.
Package insert warnings and contraindications were not available for this report. Please refer to the package insert for authoritative safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: One completed Phase 3 randomized, placebo-controlled trial, a Cochrane review, and several network meta-analyses support bupropion in adult ADHD, and its dopamine/norepinephrine mechanism is plausible. However, only one such Phase 3 trial is confirmed, bupropion is not a first-line ADHD agent, it has no valid New Zealand licence, and package insert safety data are missing.
To proceed, the following is needed:
- Medsafe package insert warnings and contraindications (blocking gap for safety screening)
- Confirmed mechanism of action data from DrugBank
- Review of the full results of NCT00048360 and the Cochrane review's conclusions on effect size and certainty
- Clarification of the study drug and design in NCT00061087
- A regulatory pathway plan, given the cancelled New Zealand licence
- A safety screening plan for seizure risk, cardiovascular effects, and psychiatric and substance-use comorbidity
Other predicted indications (for reference): ADHD, inattentive type is a subtype of the lead indication with only indirect evidence (research question stage). The remaining predictions (faciodigitogenital syndrome, specific developmental disorder, chondromyxoid fibroma, proximal 16p11.2 microdeletion syndrome, hypervitaminosis, benign paroxysmal torticollis of infancy, trigeminal nerve neoplasm, and an obsolete hypertelorism term) have no supporting clinical trials or relevant literature and should be held.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.